These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Not reported 2009-015113-44 An open label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral naive subjects: darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir 2014-11-18 due-trials
Not reported 2010-022293-14 Optimized Phase III Trial of Immuno-stimulation with Maraviroc, a CCR5 antagonist, combined with Anti Retroviral Therapy (cART) in advanced, Late diagnosed HIV-1 infected patients with an AIDS-definin... 2016-03-31 due-trials
Ongoing, reported early 2013-002607-33 Pilot study to assess efficacy and safety of Sofosbuvir/Ledipasvir (GS-5885) fixed-dose combination with Ribavirin in NS3/4A protease inhibitor-experienced subjects with HCV genotype 1 infection and H... not-yet-due
Reported results 2013-002996-16 ANRS SHS155 STIMAGO: Pilote study to evaluate the benefits and the risks of methylphenidate for the treatment of cocain dependence. ANRS SHS155 STIMAGO : Etude pilote pour l’évaluation des bénéfic... 2018-06-30 due-trials
Reported results 2013-004571-12 Evaluation of the pharmacokinetic properties and the tolerance of raltegravir during the third trimester of pregnancy Evaluation des propriétés pharmacocinétiques et de la tolérance du raltégravir... 2017-04-30 due-trials
Reported results 2014-000828-24 A non-comparative phase II trial evaluating the capacity of the dual combination raltegravir/etravirine to maintain virological success in HIV-1 infected patients of at least 45 years of age with an H... 2017-10-27 due-trials
Ongoing 2015-000511-40 Phase II, randomized, multicentric, clinical trial of a therapeutic vaccination, with ex vivo generated autologous Dentritic Cells pulsed with HIV lipopetides, combined or not with a TLR-3 agonist (po... not-yet-due
Completed, but no date 2017-000040-17 Randomized, open-label and multicentric trial evaluating the non-inferiority of antiretroviral treatment taken 4 consecutive days per week versus continuous therapy 7/7 days per week in HIV-1 infected... bad-data
Exempt, with results 2017-003081-27 A Phase I/II randomised therapeutic HIV vaccine trial in individuals who started antiretrovirals during primary or chronic infection. 2019-07-11 not-yet-due
Ongoing, reported early 2019-001961-34 ANRS 173 ALTAR A randomized, open-label, phase III trial comparing a dual nucleoside analogues strategy preceded by an induction period with an integrase inhibitor based triple therapy to an immediate... not-yet-due
Ongoing, reported early 2019-002818-40 A Phase II randomised, placebo-controlled trial of vedolizumab with or without therapeutic HIV MVA vaccine in individuals who started antiretrovirals during primary or chronic infection not-yet-due
Completed, but no date 2019-002829-29 Combined Prevention of Sexually Transmitted Infections (STIs) in Men Who Have Sex with Men using oral TDF/FTC for HIV Pre-Exposure Prophylaxis (PrEP) Prévention combinée des infections sexuellement... bad-data
Listed as ongoing, but also has a completion date 2019-004297-26 Prophylactic treatment of the ductus arteriosus in preterm infants by acetaminophen 2024-06-20 bad-data
Ongoing 2020-003951-13 Randomized, open-label and multicentric trial evaluating the non-inferiority of antiretroviral dual therapy taken 4 consecutive days per week versus antiretroviral dual therapy 7/7 days per week in HI... not-yet-due
Other 2020-004376-18 ANRS HB07 IP-cure-B proof of concept (PoC) clinical trial. Educating the liver immune environment through TLR8 stimulation followed by NUC discontinuation not-yet-due
Completed, but no date 2021-000509-26 A phase II trial assessing immunogenicity and safety of COVID-19 mRNA Vaccine BNT162b2 in adult volunteers with no history of SARS CoV-2 infection administered with two doses of vaccine (D1-D29) and i... bad-data
Other 2021-003040-25 A randomised phase II placebo-controlled trial of ART plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) vs ART plus placebo during primary HIV-1 infection to study the impact ... not-yet-due